نتائج البحث - "Juan V Apala"

المساهمون: Institut Català de la Salut, [Mouron S, Bueno MJ, Muñoz M, Apala JV] Breast Cancer Clinical Research Unit, Centro Nacional de Investigaciones Oncologicas—CNIO, Madrid, Spain. [Torres R, Rodríguez S] Molecular Cytogenetics Unit, Centro Nacional de Investigaciones Oncologicas—CNIO, Madrid, Spain. [Malumbres M] Cell Division & Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. Cancer Cell Cycle group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cancer Research, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], Oncology, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Otros calificadores::/uso terapéutico [Otros calificadores], Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Mama - Càncer - Tractament, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Other subheadings::/therapeutic use [Other subheadings], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], Proteïnes quinases - Inhibidors - Ús terapèutic

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f3d09b26dbbfec698c27a90cca9464
https://hdl.handle.net/11351/9407

5

Figure S1 from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

المؤلفون: Silvana Mouron, Francisca Mulero, Eduardo Caleiras, Diego Malón, Juan Guerra, Javier Cortés, Antonio Lopez-Alonso, María Gion, Joel Salla Fortuny, Ariadna Gasol Cudos, Manuel Muñoz, Juan V. Apala, Luis Manso, Alfonso Cortés-Salgado, Serafín Morales, Miguel Quintela-Fandino

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a157e7aab0fba6805e9a15ee8e9edbe
https://doi.org/10.1158/1078-0432.22475901

6

Supplementary Data from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

المؤلفون: Silvana Mouron, Francisca Mulero, Eduardo Caleiras, Diego Malón, Juan Guerra, Javier Cortés, Antonio Lopez-Alonso, María Gion, Joel Salla Fortuny, Ariadna Gasol Cudos, Manuel Muñoz, Juan V. Apala, Luis Manso, Alfonso Cortés-Salgado, Serafín Morales, Miguel Quintela-Fandino

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542a66c4c343909e26d1145640c2e8e5
https://doi.org/10.1158/1078-0432.22475895.v1

7

Data from Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

المؤلفون: Silvana Mouron, Francisca Mulero, Eduardo Caleiras, Diego Malón, Juan Guerra, Javier Cortés, Antonio Lopez-Alonso, María Gion, Joel Salla Fortuny, Ariadna Gasol Cudos, Manuel Muñoz, Juan V. Apala, Luis Manso, Alfonso Cortés-Salgado, Serafín Morales, Miguel Quintela-Fandino

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc3f985d5e8e7524e5de28637a2d268
https://doi.org/10.1158/1078-0432.c.6529209.v1

8

Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer

المؤلفون: Miguel Quintela-Fandino, Juan Antonio Guerra, Juan V. Apala, María Gion, Francisca Mulero, Antonio Lopez-Alonso, Alfonso Cortés-Salgado, Diego Malón, Manuel Muñoz, Javier Cortes, Ariadna Gasol Cudós, Serafin Morales, Joel Salla Fortuny, Eduardo Caleiras, Luis Manso, Silvana Mouron

المصدر: Clinical Cancer Research. 26:35-45

مصطلحات موضوعية: Adult, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Bevacizumab, Receptor, ErbB-2, Urology, Breast Neoplasms, Placebo, law.invention, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Randomized controlled trial, Fluorodeoxyglucose F18, law, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Aged, Neoplasm Staging, Aged, 80 and over, business.industry, Middle Aged, Hypoxia (medical), medicine.disease, Isoflavones, Mitochondria, Succinate Dehydrogenase, Clinical trial, Ki-67 Antigen, Treatment Outcome, 030104 developmental biology, Oncology, Positron-Emission Tomography, 030220 oncology & carcinogenesis, Pharmacodynamics, Female, Patient Safety, Radiopharmaceuticals, medicine.symptom, Energy source, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1518fa51a7c103c4c3dc49118f530580
https://doi.org/10.1158/1078-0432.ccr-19-2023

9

Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial

المساهمون: Servicio de Oncología. Hospital Universitario de Fuenlabrada, Instituto de Salud Carlos III - ISCIII, European Regional Development Fund (ERDF/FEDER), Ministerio de Economia y Competividad (MINECO), Comunidad de Madrid (España), CRIS Contra el Cancer Foundation, AstraZeneca, Instituto de Salud Carlos III, Comunidad de Madrid, UAM. Departamento de Medicina, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Ministerio de Economía y Competitividad (España), CRIS contra el Cáncer, Institut Català de la Salut, [Quintela-Fandino M] Breast Cancer Clinical Research Unit – Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain. Medical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Medical Oncology Department, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain. [Holgado E] Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. [Manso L] Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. [Morales S] Medical Oncology Department, Hospital Universitari Arnau Vilanova, Lleida, Spain. [Bermejo B] Medical Oncology Department, Hospital Clínico Universitario, Valencia, Spain. INCLIVA, Valencia, Spain. CIBERONC, Instituto Carlos III, Madrid, Spain. [Colomer R] Breast Cancer Clinical Research Unit – Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain. Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain. Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. [Cortes J] ION Institute of Oncology, Quironsalud Group – Madrid & Barcelona, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repisalud
Instituto de Salud Carlos III (ISCIII)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Biblos-e Archivo. Repositorio Institucional de la UAM
BREAST CANCER RESEARCH
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Breast Cancer Research : BCR
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Breast Cancer Research, Vol 22, Iss 1, Pp 1-14 (2020)
Scientia

مصطلحات موضوعية: Oncology, Durvalumab, Receptor, ErbB-2, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], medicine.medical_treatment, Medicaments antineoplàstics - Ús terapèutic, Angiogenesis Inhibitors, Pilot Projects, PROGRESSION, Vascular normalization, Triple Negative Breast Neoplasms, T-Lymphocytes, Regulatory, THERAPY, B7-H1 Antigen, NORMALIZATION, Antineoplastic Agents, Immunological, 0302 clinical medicine, Mama - Càncer, Surgical oncology, Antineoplastic Combined Chemotherapy Protocols, Tumor Microenvironment, Breast, skin and connective tissue diseases, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], 0303 health sciences, PROLIFERATION, Neoplasias de la Mama, Antibodies, Monoclonal, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, VEGF, Progression-Free Survival, Bevacizumab, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Immuno-priming, Disease Progression, Female, Research Article, medicine.drug, Adult, EXPRESSION, medicine.medical_specialty, Medicina, T cell, Breast Neoplasms, Antineoplastic Agents, lcsh:RC254-282, Proof of Concept Study, 03 medical and health sciences, Lymphocytes, Tumor-Infiltrating, Breast cancer, Internal medicine, medicine, Humans, terapéutica::protocolos clínicos::protocolos antineoplásicos::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasias de la Mama Triple Negativas, Aged, 030304 developmental biology, Chemotherapy, business.industry, Therapeutics::Clinical Protocols::Antineoplastic Protocols::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine.disease, Antineoplásicos, HER2-negative breast cancer, Clinical trial, Regimen, Breast neoplasms, business, 1ST-LINE

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::842a246ba615e772839387f7783c0eec
https://hdl.handle.net/20.500.12530/54354

Find this article in full text from Springer Verlag.

Find this article in full text from ProQuest

10

Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition

المؤلفون: Ramon Colomer, Juan V. Apala, Diego Malón, Juan Antonio Guerra, Miguel Quintela-Fandino, Javier Hornedo, Silvana Mouron, Lucía González-Cortijo

المساهمون: Instituto de Salud Carlos III, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Comunidad de Madrid (España), Boehringer Ingelheim Fonds, UAM. Departamento de Medicina

المصدر: Repisalud
Instituto de Salud Carlos III (ISCIII)
Breast Cancer Research : BCR
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Breast Cancer Research, Vol 21, Iss 1, Pp 1-14 (2019)
Biblos-e Archivo. Repositorio Institucional de la UAM
instname

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Indoles, Medicina, Nintedanib, Phases of clinical research, Breast Neoplasms, lcsh:RC254-282, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, FGF23, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Receptor, Fibroblast Growth Factor, Type 1, Aromatase, Protein Kinase Inhibitors, Aged, biology, Aromatase Inhibitors, business.industry, Letrozole, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Clinical trial, Fibroblast Growth Factor-23, Treatment Outcome, FGFR1, chemistry, Tolerability, Pharmacodynamics, 030220 oncology & carcinogenesis, biology.protein, Phase I clinical trial, Female, Drug Monitoring, business, Phase 0 clinical trial, Research Article, medicine.drug

وصف الملف: 14 págs.; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0f93139d823603dba7e38d119714d5
http://hdl.handle.net/20.500.12105/7806

تنقيح النتائج